300584 logo

Nanjing Hicin Pharmaceutical Co., Ltd. Stock Price

SZSE:300584 Community·CN¥5.4b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

300584 Share Price Performance

CN¥44.85
25.04 (126.40%)
CN¥44.85
25.04 (126.40%)
Price CN¥44.85

300584 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with questionable track record.

1 Risk
0 Rewards

Nanjing Hicin Pharmaceutical Co., Ltd. Key Details

CN¥615.4m

Revenue

CN¥110.5m

Cost of Revenue

CN¥504.9m

Gross Profit

CN¥460.1m

Other Expenses

CN¥44.8m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Apr 25, 2026
0.37
82.04%
7.28%
27.6%
View Full Analysis

About 300584

Founded
2003
Employees
548
CEO
Yuping Cao
WebsiteView website
www.hicin.cn

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; and raw materials, intermediates, and other products. Its products are used in cardiovascular and cerebrovascular, diuretic, anti-infection, digestive system, immune regulation, hypoglycemic, orthopedics, and other treatment areas. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is headquartered in Nanjing, China.

Recent 300584 News & Updates

Recent updates

No updates